Issue 7, 2013

A critical assessment of modeling safety-related drug attrition

Abstract

This paper challenges the general desire to find simple rules and guidelines to reduce attrition due to toxicity and clinical safety. We present an analysis of 150 AstraZeneca development compounds and evaluate some of the published guidelines and their ability to identify compounds with safety liabilities. Interestingly, none of the current guidelines were able to discriminate compounds that successfully reached Phase II. The analysis was extended to recently approved drugs (2009–2011) and we found that a large portion did not comply and would never have reached patients if such guidelines had been applied at an early stage.

Graphical abstract: A critical assessment of modeling safety-related drug attrition

Article information

Article type
Review Article
Submitted
04 Mar 2013
Accepted
15 Apr 2013
First published
16 Apr 2013

Med. Chem. Commun., 2013,4, 1058-1065

A critical assessment of modeling safety-related drug attrition

D. Muthas, S. Boyer and C. Hasselgren, Med. Chem. Commun., 2013, 4, 1058 DOI: 10.1039/C3MD00072A

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Spotlight

Advertisements